NCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
Clinical Trials
3 trialsNCT00095459 2019-12-17
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00098254 2012-05-02
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed